Repligen Corp.

As of October 31, 2025, Repligen Corp. shows a bullish technical trend supported by positive moving averages and MACD indicators, despite lagging behind the S&P 500 in year-to-date and one-year returns.

As of October 31, 2025, Repligen Corp. shows a bullish technical trend, supported by positive moving averages and MACD indicators, despite underperforming the S&P 500 over the past year and three years.

As of October 31, 2025, Repligen Corp. shows a bullish technical trend, supported by a bullish weekly MACD and daily moving averages, despite mixed signals from the monthly KST and Dow Theory, while underperforming the S&P 500 over the past 1, 3, and 5 years.

As of October 10, 2025, Repligen Corp.'s technical trend is neutral with mixed signals, showing a shift from mildly bullish to sideways, having outperformed the S&P 500 in the past month but underperformed over the longer term.

As of October 3, 2025, Repligen Corp.'s technical trend is neutral with mixed signals, showing mild bullishness in some indicators while underperforming the S&P 500 over the long term despite recent short-term gains.

As of October 3, 2025, Repligen Corp.'s technical trend is neutral with mixed indicators, showing a shift from mildly bearish to sideways, while it has outperformed the S&P 500 in the short term but lags behind on longer-term performance metrics.

As of September 8, 2025, Repligen Corp. is in a bearish trend with moderate strength, showing mixed signals across different timeframes, and has significantly underperformed the S&P 500 with a year-to-date return of -13.59% compared to the S&P's 12.22%.

As of November 12, 2024, Repligen Corp. is considered overvalued with a high P/E ratio of 210, an EV to EBITDA ratio of 56.65, and a year-to-date return of -13.59%, significantly underperforming the S&P 500.

As of November 12, 2024, Repligen Corp. is considered overvalued with a P/E ratio of 210 and an EV to EBITDA ratio of 261.48, alongside low returns on capital and equity, and has underperformed the S&P 500 by 16.56% year-to-date.

As of June 13, 2025, Repligen Corp. is in a bearish trend with strong weakness indicated by bearish MACD readings, moving averages, and KST across multiple time frames, despite some divergence in Dow Theory trends.

As of March 2022, the management team of Repligen Corp. includes Independent Chairperson Ms. Karen Dawes, President and CEO Mr. Anthony Hunt, and Directors Ms. Carrie Eglinton, Mr. Nicolas Barthelemy, Mr. Rohin Mhatre, Mr. Glenn Muir, and Mr. Thomas Ryan. They oversee the company's strategic direction and operations.

Repligen Corporation is a mid-cap bioprocessing company that develops and manufactures products to enhance biological drug manufacturing. As of March 2025, it reported net sales of $169 million and a net profit of $6 million.

As of Jun 18, Repligen Corp. has a market capitalization of $6.8 billion, with net sales of $650.43 million and a net profit of -$22.98 million over the latest four quarters.